Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells $139,809.20 in Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 3,860 shares of Apogee Therapeutics stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $36.22, for a total transaction of $139,809.20. Following the completion of the transaction, the insider now owns 247,173 shares in the company, valued at approximately $8,952,606.06. The trade was a 1.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, March 5th, Carl Dambkowski sold 1,590 shares of Apogee Therapeutics stock. The shares were sold at an average price of $30.48, for a total value of $48,463.20.
• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The stock was sold at an average price of $40.69, for a total value of $143,228.80.

Apogee Therapeutics Stock Performance

NASDAQ APGE opened at $32.32 on Friday. The stock has a market cap of $1.46 billion, a P/E ratio of -13.36 and a beta of 1.72. Apogee Therapeutics, Inc. has a fifty-two week low of $29.10 and a fifty-two week high of $63.50. The stock has a 50 day simple moving average of $37.21 and a two-hundred day simple moving average of $45.45.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). Sell-side analysts predict that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Citigroup started coverage on Apogee Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $95.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $90.00 target price on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Apogee Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $92.17.

Institutional Trading of Apogee Therapeutics

Several large investors have recently bought and sold shares of the company. Wellington Management Group LLP lifted its stake in shares of Apogee Therapeutics by 35.7% in the 3rd quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock valued at $282,798,000 after purchasing an additional 1,267,451 shares during the period. Driehaus Capital Management LLC grew its stake in Apogee Therapeutics by 2.8% in the fourth quarter. Driehaus Capital Management LLC now owns 2,605,310 shares of the company’s stock worth $118,021,000 after purchasing an additional 71,703 shares during the period. Alliancebernstein L.P. raised its holdings in Apogee Therapeutics by 13.5% in the fourth quarter. Alliancebernstein L.P. now owns 1,355,185 shares of the company’s stock worth $61,390,000 after purchasing an additional 160,822 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its position in Apogee Therapeutics by 82.9% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,283,766 shares of the company’s stock valued at $58,155,000 after buying an additional 581,949 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of Apogee Therapeutics by 141.7% during the 4th quarter. Janus Henderson Group PLC now owns 1,135,100 shares of the company’s stock valued at $51,455,000 after buying an additional 665,543 shares in the last quarter. 79.04% of the stock is owned by institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.